Cost-Effectiveness Research

Featured

Videos
Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer
Ali Khaki, MD, discusses results from a cost-effectiveness analysis comparing neoadjuvant immune checkpoint inhibition with cisplatin-based chemotherapy for muscle-invasive…
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
Vidit Sharma, MD, discusses results from a cost-effectiveness analysis comparing pembrolizumab with radical cystectomy…
News
Cost-Effectiveness of Selective Internal Radiotherapy vs Sorafenib in HCC
Compared with selective internal radiotherapy, sorafenib is not unlikely cost-effective for HCC in the United States.
News
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer
Targeted BRCA or multiple gene screening is cost-effective for preventing breast and ovarian cancer, according to a…
News
Doublet Therapy Unlikely Cost-Effective for Metastatic BRAF Variant Colorectal Cancer
While the use of doublet therapy for treating patients with metastatic BRAF variant colorectal cancer is associated…

News

Cost-Effectiveness of Selective Internal Radiotherapy vs Sorafenib in HCC
Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer
Doublet Therapy Unlikely Cost-Effective for Metastatic BRAF Variant Colorectal Cancer
RT Added to ADT Cost-Effective vs ADT Alone for Metastatic Prostate Cancer

Interviews

Discussing Biosimilars: Barriers and Cost-Effectiveness

Blog

PCORI to Incorporate Cost But Not Cost-Effectiveness in its New Principles

Videos

Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer

Podcast

Is CAR-T Therapy Comparable to Past Innovative Therapies in Regard to Health Outcomes, Cost-Effectiveness?

Conference Coverage

Nivolumab Plus Ipilimumab Cost-Effective for Intermediate or Poor Risk RCC
Back to Top